Articles from Companion Spine

Companion Spine, the French-American specialist in surgeon innovated spine implant surgery, announced that the U.S. Food and Drug Administration (the “FDA”) has approved the DIAM™ Spinal Stabilization System (P240043). DIAM™ Spinal Stabilization System is the first posterior motion-preserving device approved in the U.S. for the treatment of moderate to severe primary low back pain secondary to DDD at a single lumbar level (L2–L5) in patients who remain symptomatic after at least six months of non-operative care.

Companion Spine LLC (“Companion Spine” or “the Company”), the French-American specialist in spine implant surgery, announced today that it has completed its previously announced acquisition of the Coflex® Interlaminar Stabilization® device (“Coflex®”) and CoFix® Posterior MIS Fusion System (“CoFix®”) implants, Paradigm Spine GmbH, its subsidiaries and all Paradigm Spine-related business activity globally (“Paradigm Spine”) from Xtant™ Medical Holdings, Inc. (NYSE:XTNT) (“Xtant Medical”).

Companion Spine LLC (“Companion Spine” or “the Company”), the French-American specialist in spine pain-management surgery, announced that it has entered into a definitive agreement to acquire the Coflex® Interlaminar Stabilization® device (“Coflex®”) and CoFix® Posterior MIS Fusion System (“CoFix®”) implants, Paradigm Spine GmbH, its subsidiaries and all Paradigm Spine-related business activity globally (“Paradigm Spine”) from Xtant™ Medical Holdings, Inc. (NYSE:XTNT) (“Xtant Medical”).

Companion Spine LLC, the France-USA specialist in diagnostic and interventional spine surgery, announced today that it has raised $55 million. This Series A financing was led by Viscogliosi Brothers, the company's co-founder and historical shareholder, and jointly invested by a leading global medical technology company.